source
- Acceleron veterans and Westlake back new IPF biotech Oorja Bio with $30 million Series AEntrepreneurs who previously brought the drug Winrevair to market have launched a new biotech, Oorja Bio, to target idiopathic pulmonary fibrosis, a hard-to-treat lung disease. The company announc…
- Novo Nordisk streamlines R&D to speed discovery, adds AI to integrated research teamsNovo Nordisk's new CEO Maziar Mike Doustdar, who took the helm in the summer of 2025, announced a reorganization of the company's R&D structure. Jacob Sten Petersen, head of global research, expla…